Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Post by Northforce13on Aug 29, 2023 9:40am
296 Views
Post# 35609567

Adieu

AdieuI bid you all "adieu" fellow CPH investors, it's been a fantastic fun ride :-)

CPH remains a good stock at a decent price, but no longer a great bargain, so I have taken my winnings off the table and moved on, sold the last bits yesterday.

This was a fantastic play, The SP price growth from the entry point a couple years ago made it the largest portfolio position for a significant amount of time.

For remaining longs, potential catalysts coming down the pipe will be an acquisition, and somewhat further out, 2026... MOB015.  MOB015 took/is taking so long because Moberg is somewhat incompetent (in my opinion).   I might look at CPH again at some point before MOB015 comes out.  

CPH overall business appears to be slowly declining as Epuris loses Canadian market share.  Sharp eyes will notice that when Canadian market share was growing, they cited that figure regularly in their MD&A.  When it stopped growing, that citation mysteriously no longer seemed important for them to mention. 

GLTA
<< Previous
Bullboard Posts
Next >>